Prothena Co. plc (NASDAQ:PRTA) Shares Purchased by Barclays PLC

Barclays PLC raised its holdings in Prothena Co. plc (NASDAQ:PRTAFree Report) by 110.2% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 95,222 shares of the biotechnology company’s stock after purchasing an additional 49,916 shares during the quarter. Barclays PLC owned about 0.18% of Prothena worth $1,592,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Wellington Management Group LLP grew its holdings in shares of Prothena by 14.8% during the third quarter. Wellington Management Group LLP now owns 4,178,788 shares of the biotechnology company’s stock worth $69,911,000 after buying an additional 539,359 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Prothena by 1,122.9% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 526,748 shares of the biotechnology company’s stock worth $8,812,000 after acquiring an additional 483,673 shares during the period. Armistice Capital LLC grew its stake in shares of Prothena by 42.3% in the 2nd quarter. Armistice Capital LLC now owns 1,560,000 shares of the biotechnology company’s stock valued at $32,198,000 after purchasing an additional 464,000 shares during the last quarter. Duncan Williams Asset Management LLC acquired a new position in shares of Prothena in the third quarter valued at approximately $816,000. Finally, Federated Hermes Inc. purchased a new stake in shares of Prothena during the second quarter worth approximately $905,000. 97.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

PRTA has been the topic of a number of analyst reports. HC Wainwright reiterated a “buy” rating and issued a $48.00 price objective (down from $84.00) on shares of Prothena in a research report on Friday, December 20th. Chardan Capital assumed coverage on shares of Prothena in a report on Friday, December 20th. They issued a “buy” rating and a $40.00 target price on the stock. Bank of America dropped their price target on shares of Prothena from $26.00 to $22.00 and set a “neutral” rating on the stock in a research note on Thursday, December 19th. StockNews.com downgraded shares of Prothena from a “hold” rating to a “sell” rating in a research report on Tuesday, November 19th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Prothena in a research report on Monday, September 30th. One analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, Prothena presently has an average rating of “Moderate Buy” and an average target price of $46.50.

Get Our Latest Report on Prothena

Prothena Trading Down 7.8 %

Shares of PRTA opened at $13.05 on Friday. Prothena Co. plc has a twelve month low of $11.70 and a twelve month high of $36.20. The firm has a market capitalization of $702.21 million, a P/E ratio of -5.26 and a beta of 0.10. The firm’s 50-day moving average is $14.92 and its two-hundred day moving average is $18.39.

Prothena (NASDAQ:PRTAGet Free Report) last released its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($1.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.18) by $0.08. The business had revenue of $0.97 million for the quarter, compared to analysts’ expectations of $1.22 million. Prothena had a negative return on equity of 24.19% and a negative net margin of 98.86%. The company’s revenue was down 98.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.38 EPS. Analysts predict that Prothena Co. plc will post -2.24 EPS for the current year.

Prothena Profile

(Free Report)

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.

Further Reading

Institutional Ownership by Quarter for Prothena (NASDAQ:PRTA)

Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.